Development of Novel Mouse Monoclonal Antibodies against Human CD19

Shinji Yamada, Mika K. Kaneko, Yusuke Sayama, Teizo Asano, Masato Sano, Miyuki Yanaka, Takuro Nakamura, Saki Okamoto, Saori Handa, Yu Komatsu, Yoshimi Nakamura, Yoshikazu Furusawa, Junko Takei, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

CD19 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is expressed in normal and neoplastic B cells, and it modulates the threshold of B cell activation for amplifying B cell receptor signaling. Blinatumomab (a CD3-CD19-bispecific T cell-engaging antibody) and tisagenlecleucel (genetically modified T cells that express a CD19 chimeric antigen receptor [CART-19]) provide significant benefits for patients with CD19-positive relapsed or refractory B cell malignancies. In this study, we first employed the Cell-Based Immunization and Screening (CBIS) method to produce anti-CD19 monoclonal antibodies using CD19-overexpressing cells for both immunization and screening. One established clone - C19Mab-1 - proved to be useful in flow cytometry assays against lymphoma cell lines, such as BALL-1, P30/OHK, and Raji. Second, the extracellular domain of CD19 was immunized into mice, and enzyme-linked immunosorbent assays were performed for the first screening. One established clone - C19Mab-3 - was determined to be useful for Western blotting and immunohistochemical analysis. Due to their complementary utility, a combination of C19Mab-1 (established using CBIS) and C19Mab-3 (established using conventional method) could be useful for the pathological analysis of CD19.

Original languageEnglish
Pages (from-to)45-50
Number of pages6
JournalMonoclonal antibodies in immunodiagnosis and immunotherapy
Volume39
Issue number2
DOIs
Publication statusPublished - 2020 Apr

Keywords

  • CD19
  • hybridoma production
  • monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Development of Novel Mouse Monoclonal Antibodies against Human CD19'. Together they form a unique fingerprint.

Cite this